Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peanut Allergy
Conditions
Peanut Allergy, Multi-food Allergy
Trial Timeline
Jul 22, 2019 → Jul 1, 2025
NCT ID
NCT03881696About Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy is a phase 3 stage product being developed by Novartis for Peanut Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT03881696. Target conditions include Peanut Allergy, Multi-food Allergy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03881696 | Phase 3 | Completed |
Competing Products
20 competing products in Peanut Allergy